Patents by Inventor Naoya Tsurushita
Naoya Tsurushita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170267773Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: ApplicationFiled: May 26, 2017Publication date: September 21, 2017Applicant: Board of Regents, The University of Texas SystemInventors: Yong-Jun LIU, Kui Shin VOO, Laura BOVER, Naoya TSURUSHITA, J. Yun TSO, Shankar KUMAR
-
Patent number: 9695246Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: GrantFiled: April 13, 2015Date of Patent: July 4, 2017Assignee: Board of Regents, The University of Texas SystemInventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
-
Patent number: 9683036Abstract: Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.Type: GrantFiled: October 29, 2013Date of Patent: June 20, 2017Assignee: National Cheng Kung UniversityInventors: Ming-Shi Chang, Naoya Tsurushita, Shankar Kumar
-
Patent number: 9540442Abstract: The invention provides constant regions incorporating a cysteine mutation and linked to a ? tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and ? tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes, e.g., pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G, which facilitates purification and may exhibit pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life. Depending on the isotype and subtype, the nature of the antigen and presence of an additional IgG hinge domain, such antibodies or fusion proteins may also have properties of specific binding to protein A, and effector functions such as ADCC, CDC and opsonization.Type: GrantFiled: July 31, 2013Date of Patent: January 10, 2017Assignee: JN Biosciences LLCInventors: Naoya Tsurushita, J. Yun Tso
-
Patent number: 9527917Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: GrantFiled: September 15, 2015Date of Patent: December 27, 2016Assignee: Board of Regents, The University of Texas SystemInventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
-
Publication number: 20160369012Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.Type: ApplicationFiled: June 20, 2016Publication date: December 22, 2016Inventors: J. Yun Tso, Naoya Tsurushita
-
Publication number: 20160333110Abstract: The present invention provides: an antibody which specifically reacts with hTROP-2 and has anti-tumor activity in vivo (particularly, a humanized antibody); a hybridoma which produces the aforementioned antibody; a conjugate of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.Type: ApplicationFiled: May 31, 2016Publication date: November 17, 2016Inventors: Koji NAKAMURA, Kentaro OKAMURA, Maki TAMURA, Hiroyuki YANAI, Toru KANKE, Naoya TSURUSHITA, Shankar KUMAR
-
Patent number: 9427464Abstract: The present invention provides: an antibody which specifically reacts with hTROP-2 and has anti-tumor activity in vivo (particularly, a humanized antibody); a hybridoma which produces the aforementioned antibody; a conjugate of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.Type: GrantFiled: November 20, 2012Date of Patent: August 30, 2016Assignee: CHIOME BIOSCIENCE INC.Inventors: Koji Nakamura, Kentaro Okamura, Maki Tamura, Hiroyuki Yanai, Toru Kanke, Naoya Tsurushita, Shankar Kumar
-
Patent number: 9382319Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.Type: GrantFiled: April 3, 2014Date of Patent: July 5, 2016Assignee: JN BIOSCIENCES LLCInventors: J. Yun Tso, Naoya Tsurushita
-
Patent number: 9303086Abstract: The present invention provides: antibodies specifically reacting against hDlk-1 and having anti-tumor activity in vivo (anti-hDlk-1 antibodies, and in particular, humanized anti-hDlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent, a tumor diagnostic agent and an agent for inducing apoptosis in tumor cells, each of which comprises the aforementioned antibody or the like; a method for treating tumor, a method for detecting tumor, a method for inducing apoptosis in tumor cells, a kit for detecting and/or diagnosing tumor and a kit for inducing apoptosis in tumor cells, each of which comprises the use of the aforementioned antibody or the like; etc.Type: GrantFiled: October 3, 2013Date of Patent: April 5, 2016Assignee: LIVTECH, INC.Inventors: Koji Nakamura, Hiroyuki Yanai, Toru Kanke, Naoya Tsurushita, Shankar Kumar
-
Publication number: 20160068604Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: ApplicationFiled: September 15, 2015Publication date: March 10, 2016Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Yong-Jun LIU, Kui Shin VOO, Laura BOVER, Naoya TSURUSHITA, J. Yun TSO, Shankar KUMAR
-
Publication number: 20150315281Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: ApplicationFiled: April 13, 2015Publication date: November 5, 2015Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Yong-Jun LIU, Kui Shin VOO, Laura BOVER, Naoya TSURUSHITA, J. Yun TSO, Shankar KUMAR
-
Patent number: 9163085Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: GrantFiled: February 9, 2012Date of Patent: October 20, 2015Assignee: Board of Regents, The University of Texas SystemInventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
-
Publication number: 20150175681Abstract: Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.Type: ApplicationFiled: March 9, 2015Publication date: June 25, 2015Inventors: Dangshe Ma, Kirsten Nagashima, Brian Kennedy, Gerald P. Donovan, Yun Kang, William C. Olson, Shankar Kumar, Naoya Tsurushita, Andre J. Marozsan, Albert Cupo
-
Patent number: 9028830Abstract: The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.Type: GrantFiled: April 7, 2011Date of Patent: May 12, 2015Assignee: JN Biosciences, LLCInventors: J. Yun Tso, Naoya Tsurushita, Nicholas F. Landolfi, Shankar Kumar
-
Publication number: 20150118711Abstract: Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.Type: ApplicationFiled: October 29, 2013Publication date: April 30, 2015Applicant: NATIONAL CHENG KUNG UNIVERSITYInventors: MING-SHI CHANG, NAOYA TSURUSHITA, SHANKAR KUMAR
-
Patent number: 9006399Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: GrantFiled: August 23, 2011Date of Patent: April 14, 2015Assignee: Board of Regents, The University of Texas SystemInventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
-
Patent number: 8986697Abstract: Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.Type: GrantFiled: April 15, 2011Date of Patent: March 24, 2015Assignee: Progenics Pharmaceuticals, Inc.Inventors: Dangshe Ma, Kirsten Nagashima, Brian Kennedy, Gerald P. Donovan, Yun Kang, William C. Olson, Shankar Kumar, Naoya Tsurushita, Andre J. Marozsan, Albert Cupo
-
Publication number: 20150073130Abstract: The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and C?3 and C?4 regions of a C? constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a C? constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.Type: ApplicationFiled: November 17, 2014Publication date: March 12, 2015Applicant: JN BIOSCIENCE LLCInventors: J. Yun Tso, Naoya Tsurushita
-
Patent number: 8969539Abstract: This present invention provides an expression vector system that uses alternative RNA processing to express in a single cell a polypeptide in both membrane-bound and soluble forms. By incorporating a mimetic structure of the 3? terminal region of human mu gene and introducing other exogenous genetic elements, an artificial gene can be constructed that is capable of simultaneously expressing membrane-bound and secreted forms of polypeptides in myeloma cells and other cells of the B lymphocyte lineage, as well as in non-B cells. If an immunoglobulin heavy chain is co-expressed with a light chain using this vector, whole antibodies can be produced that are both displayed on the surface of a single cell and secreted into the cell culture supernatant. Membrane-bound antibodies facilitate isolation and expansion of those cells displaying antibodies with desired antigen binding characteristics, while secreted antibodies facilitate identification of antibodies having desired biological function(s).Type: GrantFiled: June 10, 2009Date of Patent: March 3, 2015Assignee: JN Biosciences LLCInventors: Naoya Tsurushita, J. Yun Tso